Your browser is no longer supported. Please, upgrade your browser.
Settings
ALT Altimmune, Inc. daily Stock Chart
ALT [NASD]
Altimmune, Inc.
Index- P/E- EPS (ttm)-15.41 Insider Own14.29% Shs Outstand13.75M Perf Week-2.92%
Market Cap32.04M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float12.53M Perf Month-1.27%
Income-40.00M PEG- EPS next Q- Inst Own9.40% Short Float10.25% Perf Quarter-17.38%
Sales10.60M P/S3.02 EPS this Y87.10% Inst Trans- Short Ratio4.01 Perf Half Y-26.03%
Book/sh6.25 P/B0.37 EPS next Y- ROA-71.00% Target Price10.00 Perf Year-78.93%
Cash/sh3.22 P/C0.72 EPS next 5Y- ROE-87.30% 52W Range1.70 - 36.25 Perf YTD13.11%
Dividend- P/FCF- EPS past 5Y26.20% ROI-75.80% 52W High-93.57% Beta3.06
Dividend %- Quick Ratio13.40 Sales past 5Y-10.40% Gross Margin- 52W Low37.06% ATR0.14
Employees27 Current Ratio13.40 Sales Q/Q11.10% Oper. Margin- RSI (14)44.82 Volatility4.28% 5.23%
OptionableYes Debt/Eq0.04 EPS Q/Q96.40% Profit Margin- Rel Volume0.51 Prev Close2.45
ShortableYes LT Debt/Eq0.03 EarningsAug 13 BMO Payout- Avg Volume320.05K Price2.33
Recom- SMA20-2.22% SMA50-5.56% SMA200-23.24% Volume168,743 Change-4.90%
Oct-09-17Initiated Piper Jaffray Overweight $6
Jul-15-19 07:00AM  Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc. GlobeNewswire
Jul-12-19 02:55PM  Not just a vaccine company: How this Gaithersburg biotech CEO plans to grow the business American City Business Journals
Jul-09-19 04:45PM  Altimmune to acquire California company for up to $93M American City Business Journals +6.40%
01:39PM  Germantown stem cell therapy company proposes $7M offering amid delisting threat American City Business Journals
08:48AM  Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio Benzinga
07:15AM  Altimmune's stock soars after adding NASH candidate with purchase of Spitfire Pharma MarketWatch
07:00AM  Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio GlobeNewswire
Jun-12-19 08:00AM  Altimmune Appoints Will Brown as Chief Financial Officer GlobeNewswire
Jun-10-19 08:00AM  Altimmune Announces Successful Pre-IND Meeting with FDA GlobeNewswire
Jun-05-19 08:00AM  Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs GlobeNewswire
May-14-19 04:15PM  Altimmune Announces First Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
May-08-19 08:00AM  Altimmune to Announce First Quarter 2019 Financial Results on May 15 GlobeNewswire
Apr-11-19 09:27AM  Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C. GlobeNewswire
Apr-02-19 06:30AM  Altimmune, Inc. to Host Earnings Call ACCESSWIRE -7.69%
Apr-01-19 04:20PM  Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update GlobeNewswire +12.07%
Mar-21-19 04:15PM  Altimmune to Announce Year End 2018 Financial Results on April 2 GlobeNewswire
Mar-19-19 12:21PM  Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data InvestorPlace +14.88%
08:12AM  Altimmune's stock soars on heavy volume after positive trial data of flu vaccine candidate MarketWatch
07:00AM  Altimmune Announces Positive Results from NasoVAX Extension Study GlobeNewswire
Mar-14-19 09:00AM  Altimmune to Participate at 31st Annual ROTH Conference GlobeNewswire
Mar-12-19 01:34PM  Altimmune Announces Closing of $14 Million Registered Direct Offering GlobeNewswire
Mar-08-19 09:29AM  Altimmune Announces $14 million Registered Direct Offering GlobeNewswire -36.56%
Jan-29-19 08:00AM  Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress in Vienna, Austria GlobeNewswire
Dec-14-18 07:00AM  Today's Research Reports on Trending Tickers: Sage Therapeutics and Altimmune ACCESSWIRE -10.79%
Dec-13-18 07:01AM  Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion GlobeNewswire -20.98%
Nov-30-18 06:06PM  Altimmune Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +5.59%
Nov-27-18 09:00AM  Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer GlobeNewswire
Nov-23-18 07:00AM  Today's Research Reports on Trending Tickers: Altimmune and Johnson & Johnson ACCESSWIRE
Nov-13-18 04:50PM  Altimmune Announces Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Oct-26-18 11:29AM  Altimmune to Present at Dawson James Securities 4th Annual Small Cap Growth Conference GlobeNewswire
Oct-23-18 03:05PM  Gaithersburg biotech CEO to step down American City Business Journals
Oct-17-18 08:00AM  Todays Research Reports on Stocks to Watch: Altimmune and MannKind ACCESSWIRE
Oct-08-18 12:35PM  Why Altimmune Stock Is Sliding Lower Today InvestorPlace -31.77%
09:00AM  Altimmune Announces $25 million Registered Direct Offering GlobeNewswire
Oct-03-18 08:00AM  Altimmune Closes on $16.9 Million in Funding GlobeNewswire
Oct-01-18 08:00AM  Todays Research Reports on Stocks to Watch: Aytu Bioscience and Altimmune ACCESSWIRE +13.18%
Sep-28-18 09:01AM  Altimmune Announces Pricing of $12 Million Underwritten Public Offering GlobeNewswire -49.89%
Sep-24-18 09:00AM  Altimmune Announces $4.9 million Registered Direct Offering of Common Stock GlobeNewswire -46.93%
08:00AM  Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield Development GlobeNewswire
Sep-20-18 08:00AM  Todays Research Reports on Stocks to Watch: Molecular Templates and Altimmune ACCESSWIRE +59.36%
Sep-19-18 05:16PM  Why Altimmune Stock Is Skyrocketing Today InvestorPlace +285.48%
Sep-04-18 08:00AM  Altimmune Announces Additional Positive Data from Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine GlobeNewswire
Aug-31-18 08:00AM  Altimmune Announces Initial Single-Dose Data from Its NasoShield Phase 1 Study GlobeNewswire
Aug-15-18 06:30AM  Altimmune, Inc. to Host Earnings Call ACCESSWIRE
Aug-14-18 04:01PM  Altimmune Announces Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire +9.39%
Aug-07-18 08:00AM  Altimmune to Announce Second Quarter 2018 Financial Results on August 15 GlobeNewswire
Jul-12-18 08:00AM  Altimmune Restructures Financing Agreement with Majority of the Remaining Series B Investors GlobeNewswire
Jul-10-18 08:00AM  Altimmune Appoints Mitchel Sayare as Executive Chairman of the Board, and Adds José Ochoa to Its Leadership Team as Chief Business Officer GlobeNewswire
Jun-22-18 04:15PM  Altimmune Restructures Financing Agreement GlobeNewswire
Jun-11-18 07:10AM  Stock Performance Review on Alder Biopharma and Three Other Biotech Stocks ACCESSWIRE -14.92%
Jun-05-18 06:45AM  U.S. hedge fund Hudson Bay to open London office - sources Reuters +5.62%
May-24-18 01:47PM  Does Altimmune Incs (NASDAQ:ALT) CEO Salary Reflect Performance? Simply Wall St. -7.77%
May-18-18 04:55PM  Gaithersburg biotech faces threat of stock delisting American City Business Journals
May-15-18 04:01PM  Altimmune Announces First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-08-18 06:03PM  Who Are The Major Shareholders Of Altimmune Inc (NASDAQ:ALT)? Simply Wall St.
08:00AM  Altimmune to Announce First Quarter 2018 Financial Results on May 16 GlobeNewswire
Apr-19-18 07:40AM  Free Research Report as ChemoCentryxs Quarterly Revenues Zoomed More than 1000%; Turned Profitable Y-O-Y ACCESSWIRE
Mar-28-18 04:44PM  Altimmune Announces Financial Results for the Year Ended December 31, 2017 and Provides Corporate Update GlobeNewswire -13.04%
11:10AM  Heres Whats Moving Esperion And Altimmune, Inc. Market Exclusive
Mar-27-18 08:00AM  Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection GlobeNewswire -17.86%
Mar-22-18 04:01PM  Altimmune to Participate at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-20-18 04:01PM  Altimmune to Announce Year End 2017 Financial Results on March 29 GlobeNewswire
Mar-12-18 04:34PM  Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program GlobeNewswire
Mar-06-18 08:00AM  Altimmune to Participate at Two Investor Conferences in March GlobeNewswire -5.73%
Jan-23-18 08:00AM  Altimmune Announces Notice of Allowance on Patent Covering Use of NasoShield in the U.S. GlobeNewswire
Jan-22-18 08:00AM  Altimmune to Participate at the Noble Capital 14th Annual Investor Conference GlobeNewswire
Jan-05-18 12:00PM  Should You Be Concerned About Altimmune Incs (NASDAQ:ALT) Investors? Simply Wall St.
Jan-03-18 08:00AM  Altimmune Elects Mitchel Sayare, Ph.D. as Chairman of its Board of Directors GlobeNewswire
Dec-28-17 12:45PM  Is Altimmune Incs (NASDAQ:ALT) CEO Paid At A Competitive Rate? Simply Wall St. +8.17%
Dec-22-17 11:31AM  ETFs with exposure to Altimmune, Inc. : December 22, 2017 Capital Cube
Dec-21-17 04:01PM  Altimmune to Participate in the 10th Annual Biotech Showcase in San Francisco, January 8 10, 2018 GlobeNewswire
08:00AM  Altimmune Announces Positive Initial Data from Its HepTcell Phase 1 Study GlobeNewswire
Dec-11-17 01:25PM  ETFs with exposure to Altimmune, Inc. : December 11, 2017 Capital Cube
08:00AM  Altimmune Submits Investigational New Drug Application for NasoShield in Preparation for its Phase 1 Trial GlobeNewswire
Nov-30-17 01:15PM  ETFs with exposure to Altimmune, Inc. : November 30, 2017 Capital Cube -6.22%
Nov-21-17 08:00AM  Altimmune to Present at the 29th Annual Piper Jaffray Conference GlobeNewswire
Nov-20-17 11:31AM  ETFs with exposure to Altimmune, Inc. : November 20, 2017 Capital Cube
Nov-17-17 08:34AM  Altimmune, Inc. :ALT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 17, 2017 Capital Cube
Nov-09-17 04:01PM  Altimmune Announces Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Nov-02-17 08:00AM  Altimmune to Announce Third Quarter 2017 Financial Results on November 9 GlobeNewswire
Oct-25-17 09:48AM  ETFs with exposure to Altimmune, Inc. : October 25, 2017 Capital Cube
Oct-10-17 10:58AM  ETFs with exposure to Altimmune, Inc. : October 10, 2017 Capital Cube
Sep-22-17 04:56PM  Whats Ahead For Altimmune Inc (ALT)? Simply Wall St.
Sep-20-17 08:00AM  Altimmune Announces its Phase 2 Flu Vaccine Trial with NasoVAX Open for Enrollment GlobeNewswire +5.42%
Sep-19-17 08:00AM  Altimmune to Provide Corporate Update at the Ladenburg Thalmann 3rd Annual Healthcare Conference GlobeNewswire
Sep-06-17 08:00AM  Altimmune to Provide Corporate Update at the Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-25-17 03:44PM  ETFs with exposure to Altimmune, Inc. : August 25, 2017 Capital Cube
Aug-23-17 07:11AM  Maryland biotech expanding into new Gaithersburg headquarters American City Business Journals
Aug-21-17 04:01PM  Altimmune Closes Series B Preferred Stock Offering GlobeNewswire
08:00AM  Altimmune Submits Investigational New Drug Application for NasoVAX in Preparation for Phase 2 Trial GlobeNewswire
Aug-18-17 08:35PM  [$$] Investors Give Altimmune $14.7 Million Boost Following Reverse Merger The Wall Street Journal
Aug-17-17 10:09AM  Altimmune, Inc. :ALT-US: Earnings Analysis: Q2, 2017 By the Numbers : August 17, 2017 Capital Cube -5.99%
08:00AM  Altimmune Announces $14.7 Million Series B Preferred Stock Offering GlobeNewswire
Aug-10-17 12:25AM  Altimmune Announces Second Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
Jul-31-17 08:00AM  Altimmune to Announce Second Quarter 2017 Financial Results on August 10 GlobeNewswire -6.32%
Jul-11-17 02:00PM  ETFs with exposure to Altimmune, Inc. : July 11, 2017 Capital Cube
Jun-19-17 08:00AM  Altimmune to Provide Corporate Update at the BIO International Convention GlobeNewswire
Jun-16-17 03:21PM  ETFs with exposure to Altimmune, Inc. : June 16, 2017 Capital Cube
May-16-17 08:00AM  Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer GlobeNewswire
May-11-17 10:45AM  Altimmune, Inc. :ALT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 11, 2017 Capital Cube
Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pisano WayneDirectorOct 09Buy4.592,0009,1802,000Oct 11 04:18 PM